Current and historical daily PE Ratio for DBV Technologies SA (
) from 2013 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. DBV Technologies stock (DBVTF) PE ratio as of Jun 10 2024 is 0.
More Details
DBV Technologies SA (DBVTF) PE Ratio (TTM) Chart
DBV Technologies SA (DBVTF) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1050
- 1
- 2
- 3
- 4
- 5
- 6
- 12
DBV Technologies PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-10 | At Loss | 2023-06-26 | At Loss |
2023-08-29 | At Loss | 2023-06-23 | At Loss |
2023-08-28 | At Loss | 2023-06-22 | At Loss |
2023-08-25 | At Loss | 2023-06-21 | At Loss |
2023-08-24 | At Loss | 2023-06-20 | At Loss |
2023-08-23 | At Loss | 2023-06-16 | At Loss |
2023-08-22 | At Loss | 2023-06-15 | At Loss |
2023-08-21 | At Loss | 2023-06-14 | At Loss |
2023-08-18 | At Loss | 2023-06-13 | At Loss |
2023-08-17 | At Loss | 2023-06-12 | At Loss |
2023-08-16 | At Loss | 2023-06-09 | At Loss |
2023-08-15 | At Loss | 2023-06-08 | At Loss |
2023-08-14 | At Loss | 2023-06-07 | At Loss |
2023-08-11 | At Loss | 2023-06-06 | At Loss |
2023-08-10 | At Loss | 2023-06-05 | At Loss |
2023-08-09 | At Loss | 2023-06-02 | At Loss |
2023-08-08 | At Loss | 2023-06-01 | At Loss |
2023-08-07 | At Loss | 2023-05-31 | At Loss |
2023-08-04 | At Loss | 2023-05-30 | At Loss |
2023-08-03 | At Loss | 2023-05-26 | At Loss |
2023-08-02 | At Loss | 2023-05-25 | At Loss |
2023-08-01 | At Loss | 2023-05-24 | At Loss |
2023-07-31 | At Loss | 2023-05-23 | At Loss |
2023-07-28 | At Loss | 2023-05-22 | At Loss |
2023-07-27 | At Loss | 2023-05-19 | At Loss |
2023-07-26 | At Loss | 2023-05-18 | At Loss |
2023-07-25 | At Loss | 2023-05-17 | At Loss |
2023-07-24 | At Loss | 2023-05-16 | At Loss |
2023-07-21 | At Loss | 2023-05-15 | At Loss |
2023-07-20 | At Loss | 2023-05-12 | At Loss |
2023-07-19 | At Loss | 2023-05-11 | At Loss |
2023-07-18 | At Loss | 2023-05-10 | At Loss |
2023-07-17 | At Loss | 2023-05-09 | At Loss |
2023-07-14 | At Loss | 2023-05-08 | At Loss |
2023-07-13 | At Loss | 2023-05-05 | At Loss |
2023-07-12 | At Loss | 2023-05-04 | At Loss |
2023-07-11 | At Loss | 2023-05-03 | At Loss |
2023-07-10 | At Loss | 2023-05-02 | At Loss |
2023-07-07 | At Loss | 2023-05-01 | At Loss |
2023-07-06 | At Loss | 2023-04-28 | At Loss |
2023-07-05 | At Loss | 2023-04-27 | At Loss |
2023-06-30 | At Loss | 2023-04-26 | At Loss |
2023-06-29 | At Loss | 2023-04-25 | At Loss |
2023-06-28 | At Loss | 2023-04-24 | At Loss |
2023-06-27 | At Loss | 2023-04-21 | At Loss |
DBV Technologies SA (DBVTF) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![DBV Technologies SA DBV Technologies SA logo](https://static.gurufocus.com/logos/0C00009AEX.png?14)
DBV Technologies SA
NAICS : 325412
SIC : 2834
ISIN : FR0010417345
Share Class Description:
DBVTF: Ordinary SharesCompare
Compare
Traded in other countries / regions
DBV.FranceDBVT.USADBV.Germany0QAJ.UK IPO Date
2013-09-11Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.